AstraZeneca has announced a three-month extension to the FDA’s review period for camizestrant, a promising treatment for HR+/HER2- advanced breast cancer with ESR1 mutations.
GSK is set to demonstrate the strength of its oncology pipeline at major 2026 congresses, highlighting long-term outcomes for Jemperli and Blenrep alongside new GIST data.
Merck has announced that the Phase 3 Trofuse-005 trial evaluating Sacituzumab Tirumotecan (Sac-TMT) successfully met its primary endpoints, offering a new hope for patients with advanced or metastatic NSCLC.
Novartis has announced groundbreaking results from the Phase III PSMAddition trial, revealing that Pluvicto significantly reduces the risk of PSA progression by 58% in patients with metastatic hormone-sensitive prostate cancer.
AstraZeneca and Daiichi Sankyo’s Enhertu achieves milestone FDA approvals in two early-stage HER2-positive breast cancer settings, reshaping curative care.
AstraZeneca announces positive results from the EMERALD-2 Phase III trial, proving that the Imfinzi and Imjudo liver cancer treatment significantly delays disease recurrence in patients following surgery or ablation.
In a landmark development for personalized medicine, Moderna, Inc. and Merck (known as MSD outside the U.S. and Canada) announced today that their investigational mRNA-based [Read More…]
NEW BRUNSWICK, N.J., November 17, 2025 — Johnson & Johnson (NYSE: JNJ) said today that it has reached a final deal to pay $3.05 billion [Read More…]
Results from the ASCENT-03 study reveal that Trodelvy (sacituzumab govitecan-hziy) significantly enhances outcomes for patients with metastatic triple-negative breast cancer. The drug lowered the risk of disease progression or death by 38% and provided a longer duration of response compared to chemotherapy. This positions Trodelvy as a potential new standard of care for this aggressive form of breast cancer, offering hope to a patient population with limited treatment options.
A landmark clinical trial reveals a powerful new weapon against aggressive bladder cancer. The combination of PADCEV™ and KEYTRUDA®, administered before and after surgery, has been shown to significantly improve survival rates for patients with muscle-invasive bladder cancer who are ineligible for cisplatin chemotherapy. These groundbreaking results could establish a new standard of care, offering profound hope for a patient population with previously limited options.
